These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30311444)

  • 21. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.
    Tan G; Xie B; Yu N; Huang J; Zhang B; Lin F; Li H
    Int J Clin Oncol; 2021 Mar; 26(3):532-542. PubMed ID: 33387087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BEX1 mediates sorafenib resistance in hepatocellular carcinoma by regulating AKT signaling.
    Zhuang N; Gu Z; Feng J; Chai Z; Shan J; Qian C
    Cell Signal; 2023 Aug; 108():110722. PubMed ID: 37209973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid hormone T3 augments the cytotoxicity of sorafenib in Huh7 hepatocellular carcinoma cells by suppressing AKT expression.
    Uyulgan S; Köse SN; Kıpçak A; Başkan Y; Dağlar G; Karagonlar ZF; Yandım C
    J Cancer Res Ther; 2024 Apr; 20(3):755-762. PubMed ID: 39023579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
    Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.
    Li J; Wu PW; Zhou Y; Dai B; Zhang PF; Zhang YH; Liu Y; Shi XL
    Cell Death Dis; 2018 Feb; 9(2):225. PubMed ID: 29445087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.
    Tan XL; Wang Z; Liao S; Yi M; Tao D; Zhang X; Leng X; Shi J; Xie S; Yang Y; Liu YQ
    Cancer Sci; 2024 Feb; 115(2):465-476. PubMed ID: 37991109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
    Chen Y; Pan B; Qiu J; Chen Z; Wang X; Tang N
    Toxicol In Vitro; 2021 Oct; 76():105226. PubMed ID: 34293431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
    Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
    Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
    Gao M; Kong Q; Hua H; Yin Y; Wang J; Luo T; Jiang Y
    Oncotarget; 2016 Mar; 7(13):16349-61. PubMed ID: 26918349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
    Son Y; Shin NR; Kim SH; Park SC; Lee HJ
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
    Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
    Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
    Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
    Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
    Liu J; Nie C
    Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.